Drug Trial Radar · NCT04348383
Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.
Last checked: Nov 20, 2026Latest source record: Jun 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Apr 8, 2020
Primary completion
Feb 28, 2023
Study completion Feb 28, 2023
Sponsor
- Lead sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Protection of endothelial dysfunction by intravenous infusion of Defibrotide (Defitelio), expected to decrease inflammation and expression of adhesion molecules in the endothelium, leukocyte tissue infiltration and epithelial destruction, and to promote immune tolerance through a change in the Cytokine balance, which is decisive in preventing multiorgan failure and death in patients with SARS-CoV-2 infection with clinical status grade 4 or 5 according to the WHO classification
Conditions
- COVID19
Interventions
DefibrotideDrug
6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
PlaceboDrug
Placebo 250 cc every 6 hours for 7 or15 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical improvement.Time frame: 7,15, 30 day
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Hospital Clinico y Provincial de Barcelona
Barcelona, Spain
Virgen de la Arrixaca University Clinical Hospital
Murcia, Spain
Hospital General Universitario Morales Meseguer
Murcia, Spain
Hospital General Universitario Reina Sofía
Murcia, Spain
Hospital Universitario Salamanca
Salamanca, Spain
Hospital General Universitario Santa Lucía
Cartagena, Murcia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.